No sides. Just data.

We compare what the media report with what the data say

Health · India

Why India rejected a patent application for shorter drug-resistant TB treatment | Explained

Outlet: The Hindu · Published 29/10/2026 07:52 UTC

This story is compared across 2 outlets: see the comparison →

The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care

Read on the original outlet ↗

Capture record
Source
https://www.thehindu.com/sci-tech/health/why-india-rejected-a-patent-application-for-shorter-drug-resistant-tb-treatment-explained/article71639506.ece
Published
29/10/2026 07:52 UTC
Captured
29/10/2026 08:09 UTC
Text fingerprint
faba298041a5d40c · 1006 words
Changes detected
0
Archived copy
Wayback Machine ↗

The fingerprint (sha256) and the capture date prove what the story said when we analysed it, even if it changes later.

More contrasts in health